Michael Silverberg to RNA, Viral
This is a "connection" page, showing publications Michael Silverberg has written about RNA, Viral.
Connection Strength
0.827
-
Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data. AIDS Behav. 2020 Jun; 24(6):1784-1792.
Score: 0.183
-
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
Score: 0.151
-
Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23; 24(16):2469-79.
Score: 0.094
-
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
Score: 0.076
-
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
Score: 0.048
-
Demographic, Insurance, and Health Characteristics of Newly Enrolled HIV-Positive Patients After Implementation of the Affordable Care Act in California. Am J Public Health. 2016 07; 106(7):1211-3.
Score: 0.034
-
Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
Score: 0.033
-
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013 Oct 15; 208(8):1240-9.
Score: 0.029
-
Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
Score: 0.026
-
Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
Score: 0.025
-
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
Score: 0.021
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.021
-
Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
Score: 0.020
-
Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
Score: 0.020
-
Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
Score: 0.018
-
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005 Apr 20; 97(8):577-86.
Score: 0.016
-
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
Score: 0.013